Research graph
References from Generational safety profiles of BTK inhibitors: adverse reaction signals and real-world evidence from the FAERS database. Local targets link to admitted publications; unresolved targets remain external evidence.
Targeting btk in B cell malignancies: from mode of action to resistance mechanisms
10.3390/ijms25063234 · 2024 · External reference
Btk inhibitors resistance in B cell malignancies: mechanisms and potential therapeutic strategies
10.1016/j.blre.2025.101273 · 2025 · External reference
Btk inhibitors and next-generation Btk-targeted therapeutics for B-cell malignancies
10.1007/s12272-025-01546-0 · 2025 · External reference
Inhibitors targeting Bruton's Tyrosine kinase in cancers: drug development advances
10.1038/s41375-020-01072-6 · 2021 · External reference
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
10.1056/nejmoa1400376 · 2014 · External reference
Mantle cell lymphoma in 2022-a comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments
10.1002/ajh.26523 · 2022 · External reference
How I use genomics and Btk inhibitors in the treatment of waldenström macroglobulinemia
10.1182/blood.2022017235 · 2024 · External reference
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
10.1056/nejmoa1509388 · 2015 · External reference
Long-Term efficacy and safety of first-line ibrutinib treatment for patients with Cll/Sll: 5 years of follow-up from the phase 3 resonate-2 study
10.1038/s41375-019-0602-x · 2020 · External reference
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the elevate-rr trial
10.1182/blood.2022018818 · 2023 · External reference
Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R Cll/Sll: final comparative analysis of alpine
10.1182/blood.2024024667 · 2024 · External reference
The guidelines for diagnosis and treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma in China (2025)
10.3760/cma.j.cn121090-20241209-00551 · 2025 · External reference
Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) btk inhibitor
10.1182/blood.2022018674 · 2023 · External reference
Pirtobrutinib: first approval
10.1007/s40265-023-01860-1 · 2023 · External reference
Bruton’s tyrosine kinase inhibition as an emerging therapy in systemic autoimmune disease
10.1007/s40265-021-01592-0 · 2021 · External reference
Bruton’s tyrosine kinase inhibitors: recent updates
10.3390/ijms25042208 · 2024 · External reference
Ibrutinib's off-target mechanism: cause for dose optimization
10.1080/15384047.2021.1980313 · 2021 · External reference
Ibrutinib-Associated atrial fibrillation
10.1016/j.jacep.2018.06.004 · 2018 · External reference
Ibrutinib has time-dependent on- and off-target effects on plasma biomarkers and immune cells in chronic lymphocytic leukemia
10.1097/hs9.0000000000000564 · 2021 · External reference
Novel mechanisms of resistance in Cll: variant btk mutations in second-generation and noncovalent Btk inhibitors
10.1182/blood.2024026672 · 2025 · External reference
Pirtobrutinib targets btk C481s in ibrutinib-resistant cll but second-site Btk mutations lead to resistance
10.1182/bloodadvances.2022008447 · 2023 · External reference
Cardiovascular toxicities of ibrutinib: a pharmacovigilance study based on the United States food and drug administration adverse event reporting system database
10.3390/ph16010098 · 2023 · External reference
Post-Marketing safety evaluation of zanubrutinib: a real-world pharmacovigilance analysis based on the faers database
10.1080/14740338.2025.2465872 · 2026 · External reference
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic waldenström macroglobulinemia: the aspen study
10.1182/blood.2020006844 · 2020 · External reference
Investigating overlap in signals from evdas, faers, and vigibase(®)
10.1007/s40264-019-00899-y · 2020 · External reference
Data mining and safety analysis of btk inhibitors: a pharmacovigilance investigation based on the faers database
10.3389/fphar.2022.995522 · 2022 · External reference
Investigating bleeding adverse events associated with Btk inhibitors in the food and drug administration adverse event reporting system (faers)
10.1080/14740338.2024.2339448 · 2025 · External reference
A real-world pharmacovigilance study of fda adverse event reporting system (faers) events for bruton’s tyrosine kinase inhibitors (btkis) single and its combination therapy
10.1080/14740338.2024.2327507 · 2024 · External reference
Exploring the association of disease-modifying therapies for multiple sclerosis and btk inhibitors with epilepsy
10.1177/17562864241276204 · 2024 · External reference
Risk of musculoskeletal disorders associated with bruton’s tyrosine kinase inhibitors: a disproportionality analysis of faers database and meta-analysis
10.1080/14740338.2025.2521358 · 2025 · External reference
Urinary tract infection following the use of btk inhibitors: a real-world analysis of post-marketing surveillance data
10.1080/14740338.2023.2251376 · 2024 · External reference
Delta-8, a Cannabis-derived tetrahydrocannabinol isomer: evaluating case report data in the food and drug administration adverse event reporting system (faers) database
10.2147/dhps.s391857 · 2023 · External reference
The medical dictionary for regulatory activities (meddra)
10.2165/00002018-199920020-00002 · 1999 · External reference
Missing data in clinical research: a tutorial on multiple imputation
10.1016/j.cjca.2020.11.010 · 2021 · External reference
A practical guide to multiple imputation of missing data in nephrology
10.1016/j.kint.2020.07.035 · 2021 · External reference
Data mining of the public version of the fda adverse event reporting system
10.7150/ijms.6048 · 2013 · External reference
Selected control events and reporting odds ratio in signal detection methodology
10.1002/pds.2014 · 2010 · External reference
Validation of statistical signal detection procedures in eudravigilance post-authorization data
10.2165/11534410-000000000-00000 · 2010 · External reference
Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the Us Fda’s spontaneous reports database
10.2165/00002018-200225060-00001 · 2002 · External reference
A Bayesian neural network method for adverse drug reaction signal generation
10.1007/s002280050466 · 1998 · External reference
Extending the methods used to screen the who drug safety database towards analysis of Complex associations and improved accuracy for rare events
10.1002/sim.2473 · 2006 · External reference
Practical pharmacovigilance analysis strategies
10.1002/pds.771 · 2003 · External reference
Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the Fda adverse event reporting system
10.1007/s11523-024-01058-9 · 2024 · External reference
Part 21: categoric analysis: pearson chi-square test
10.1016/j.amj.2013.04.007 · 2013 · External reference
Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer
10.1093/jnci/djad186 · 2024 · External reference
Multiple significance tests: the Bonferroni correction
10.1136/bmj.e509 · 2011 · External reference
The strengthening the reporting of observational studies in epidemiology (strobe) statement: guidelines for reporting observational studies
10.1016/j.ijsu.2014.07.013 · 2014 · External reference
Does gender matter in non-hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy
10.5041/rmmj.10172 · 2014 · External reference
Sex differences in lymphoma incidence and mortality by subtype: a population-based study
10.1002/ajh.26744 · 2023 · External reference
Trends of non-hodgkin lymphoma incidence among adults in the United States from 2000 to 2020
10.1002/cnr2.70269 · 2025 · External reference
Formation of Cyp3a-specific metabolites of ibrutinib in vitro is correlated with hepatic Cyp3a activity and 4β-hydroxycholesterol/cholesterol ratio
10.1111/cts.13448 · 2023 · External reference
The evolution of therapies targeting bruton tyrosine kinase for the treatment of chronic lymphocytic leukaemia: future perspectives
10.3390/cancers15092596 · 2023 · External reference
How will B-cell-receptor-targeted therapies change future cll therapy?
10.1182/blood-2013-09-453092 · 2014 · External reference
Coming of age for Btk inhibitor therapy: a review of zanubrutinib in waldenström macroglobulinemia
10.3390/cells11203287 · 2022 · External reference
Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia
10.1056/nejmoa2211582 · 2023 · External reference
The evolving role of bruton's tyrosine kinase inhibitors in B cell lymphomas
10.3390/ijms25147516 · 2024 · External reference
Pirtobrutinib in relapsed or refractory B-cell malignancies (bruin): a phase 1/2 study
10.1016/s0140-6736(21)00224-5 · 2021 · External reference
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 2.2024, nccn clinical practice guidelines in oncology
10.6004/jnccn.2024.0018 · 2024 · External reference
Navigating the changing landscape of Btk-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
10.1038/s41571-024-00956-1 · 2024 · External reference
Monitoring and managing Btk inhibitor treatment-related adverse events in clinical practice
10.3389/fonc.2021.720704 · 2021 · External reference
Cardiovascular toxicities of Btk inhibitors in chronic lymphocytic leukemia: Jacc: cardiooncology state-of-the-art review
10.1016/j.jaccao.2023.09.002 · 2023 · External reference
Btki-Induced cardiovascular toxicity in Cll: risk mitigation and management strategies
10.1016/j.blre.2025.101268 · 2025 · External reference
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients
10.3324/haematol.2021.278901 · 2022 · External reference
Bruton’s tyrosine kinase inhibitor-related cardiotoxicity: the quest for predictive biomarkers and improved risk stratification
10.18632/oncotarget.28589 · 2024 · External reference
Cardiovascular safety of bruton tyrosine kinase inhibitors: from ibrutinib to next-generation agents
10.1007/s40256-025-00757-6 · 2025 · External reference
The immunomodulatory mechanisms of btk inhibition in cll and beyond
10.3390/cancers16213574 · 2024 · External reference
Comparative analysis of btk inhibitors and mechanisms underlying adverse effects
10.3389/fcell.2021.630942 · 2021 · External reference
Esmo clinical practice guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia
10.1016/j.annonc.2024.06.016 · 2024 · External reference
Evidence-Based expert consensus on clinical management of safety of bruton's tyrosine kinase inhibitors (2024)
10.21147/j.issn.1000-9604.2024.03.02 · 2024 · External reference
Effect of aspirin on all-cause mortality in the healthy elderly
10.1056/nejmoa1803955 · 2018 · External reference
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
10.3324/haematol.2017.182907 · 2018 · External reference
Pirtobrutinib in Chinese patients with relapsed or refractory B-cell malignancies: a single-arm, open-label, phase 2, multicenter trial
10.1002/ijc.35339 · 2025 · External reference
